Welcome to BioInsights

bringing you the latest cutting-edge research and commentary in bioscience

Peer-reviewed, Open Access Publications

Bringing you the latest research, reviews and updates from across the sectors:

Cell and Gene Therapy Insights

Learn more

Immuno-oncology Insights

Learn more

Your content marketing partner for life sciences

Roundtables and Webinars

Present a webinar or roundtable with us:

  • Generate qualified leads
  • Demonstrate your company’s expertise and capabilities
  • Stimulate discussion around a topic of significant importance
  • Educate individuals on crucial regulatory, scientific or technical issues
  • Make a noise around a new product or service offering launch

Get in touch to see how we can partner with you

Get in touch

Articles and podcasts

Peer-reviewed, open access publications

  • Generate qualified leads
  • Demonstrate your company’s expertise and capabilities
  • Stimulate discussion around a topic of significant importance
  • Educate individuals on crucial regulatory, scientific or technical issues
  • Make a noise around a new product or service offering launch
Find out more

Latest Content

Breaking viral vector bioanalysis barriers with centrifugal...

P Ahrweiler
Patricia Ahrweiler
Gyros Protein Technologies
16 March 2021
Innovator Insight

Update on new viral vector strategies in gene therapy

C Glover
Clive Glover
Director, Strategy at Pall Corporation
Dr Clive Glover is the Director, Strategy at Pall Biotech where he leads Pall’s cell and gene therapy business. Previously he was responsible for driving product development efforts around cell therapy at GE Healthcare and has also held positions in marketing and product management at STEMCELL Technologies. Clive holds a PhD in Genetics from the University of British Columbia.
25 February 2021

Preclinical/translational tools & strategies

B Bunnell
Bruce A Bunnell
Professor and Chair, Department of Microbiology, Immunology and Genetics, University if North Texas Health Science Center, Fort Worth, TX, USA 76107
Bruce A Bunnell is a professor and Chair of the Department of Microbiology, Immunology and Genetics at the University of North Texas Health Science Center in Fort Worth, TX. Previously, he served as Director of the Tulane Center for Stem Cell Research and Regenerative Medicine and Professor in the Department of Pharmacology in the Tulane University School of Medicine. Dr. Bunnell obtained his PhD in Microbiology from the University of Alabama at Birmingham School of Medicine. He then pursued Postdoctoral Fellowship research at the Howard Hughes Medical Institute in the School of Medicine at the University of Michigan and the National Human Genome Research Institute at the National Institutes of Health in Bethesda, MD. Dr. Bunnell was an Assistant Professor at the Nationwide Children’s Hospital Research Institute, part of the Ohio State University School of Medicine prior to joining the faculty at Tulane University in 2002. Dr. Bunnell’s research program is focused on both the basic science and translational applications of adult stem cells isolated from the bone marrow and adipose tissue. Dr. Bunnell investigates use of mesenchymal stem cells (MSCs) isolated from the bone marrow or adipose tissue as a therapeutic intervention for both multiple sclerosis (MS) wound repair, lung injury and bone repair. He is particularly interested the interactions of MSC with the immune system and how the cells elicit robust anti-inflammatory effects in vivo. He is currently working towards a human clinical trials for the treatment of osteoarthritis, traumatic brain injury and MS with these cells. He has served as a reviewer of stem cell, regenerative medicine and tissue engineering grants for the National Institutes of Health, Department of Defense and several state funded programs including Maryland, New York, Virginia and Pennsylvania. He has also served on grant review panels for several foreign countries including Denmark, Ireland, Poland, Germany and Spain. Dr. Bunnell serves as an Editorial Board Member for several journals, including Stem Cells, BMC Genomics, and Regenerative Medicine.
24 February 2021

Identify and select optimal T cell phenotypes

J Lovrgen
James Lovrgen
Vice President, Cell Therapy Marketing Berkeley Lights
22 February 2021

The importance of a strong collection cell collection network...

C McClain
Chris McClain, MBA
Senior Vice President, Sales and Business Development Be The Match BioTherapies®
Chris McClain is the Senior Vice President of Sales and Business Development for Be The Match BioTherapies. He leads the sales and business development team, which engages with companies developing innovative, lifesaving therapies that can leverage the cell sourcing, cell therapy supply chain, CRO services, and outcomes tracking capabilities of the National Marrow Donor Program (NMDP) / Be The Match.Before joining Be the Match BioTherapies full-time, Chris was co-Founder of Nora Therapeutics, Inc., a venture-backed biopharmaceutical company developing novel therapies in areas of significant unmet medical need in reproductive health. While at Nora Therapeutics, Chris and his team raised more than $50 million in venture capital to fund pre-clinical and clinical development of Nora’s lead asset and build out a world-class executive team. Prior to founding Nora Therapeutics, Chris held a variety of management consulting and operational roles in the technology sector.He has served as an advisory member of the University of Minnesota Office for Technology Commercialization Venture Center, a guest lecturer in the Life Sciences program at the University of Minnesota’s Carlson Graduate School of Management, a mentor to the annual MNCup startup competition, and a co-chair of Medical Alley’s Biotech Shared Interest Group.Chris has an MBA and B.A. in Economics from the University of California, Berkeley.
11 February 2021

Towards an integrated understanding of immunotherapy resistance

B Hanks
Brent A Hanks
Associate Professor of Medical Oncology in the Department of Medicine and Assistant Professor in the Department of Pharmacology and Cancer Biology, Duke University
11 February 2021